dr. reddy's labs glp-1 receptor agonist Laboratories has entered the fast-growing therapy segment with the launch of its semaglutide generic, Obeda, for Type 2 diabetes in India's โน1,446 crore market. ๐๐๐๐ ๐๐ฎ๐ฅ๐ฅ ๐๐ซ๐ญ๐ข๐๐ฅ๐ ๐จ๐ง ๐จ๐ฎ๐ซ With the launch of Obedaยฎ,
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 25 - Aug 30




:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)


:max_bytes(150000):strip_icc()/VWH-AmeliaManley-OzempicvsWegovyvsMounjaro-dc80b8c8de6243ec9b984cd4b5db5db4.jpg)


![tirzepatide court UPDATE [March 7, 2025]: OFA takes case to appeals as legal battle evolves FDA's tirzepatide decision creates uncertainty court ruling on tirzepatide case โ](https://static.wixstatic.com/media/60489a_95b142b425f4416b99f8a052fde88da7~mv2.jpg/v1/fill/w_980,h_551,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/60489a_95b142b425f4416b99f8a052fde88da7~mv2.jpg)











